Phase 3 Clinical Trials With Primary Completion Dates in June 2025
This is a list of Phase 3 trials with primary completion dates in June 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals, Inc. | 2025-06-01 | Phase 3 | NCT03531255 | Pegcetacoplan Long Term Safety and Efficacy Extension Study |
| ASCLF | Ascletis Pharma Inc. | 2025-06-01 | Phase 3 | NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM |
| AYTU | Aytu BioPharma, Inc. | 2025-06-01 | Phase 3 | NCT05463679 | Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. |
| BHVN | Biohaven Ltd. | 2025-06-01 | Phase 3 | NCT04641143 | Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder |
| BSPM | Biostar Pharmaceuticals, Inc. | 2025-06-01 | Phase 3 | NCT05430399 | Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer |
| IONS | Ionis Pharmaceuticals, Inc. | 2025-06-01 | Phase 3 | NCT05552326 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia |
| MIST | Milestone Pharmaceuticals Inc. | 2025-06-01 | Phase 3 | NCT04952610 | Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia |
| NPCE | NeuroPace, Inc. | 2025-06-01 | Phase 3 | NCT05147571 | RNS System NAUTILUS Study |
| PRTA | Prothena Corporation plc | 2025-06-01 | Phase 3 | NCT04973137 | A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis |
| VTGN | Vistagen Therapeutics, Inc. | 2025-06-01 | Phase 3 | NCT06358651 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3) |
| XENE | Xenon Pharmaceuticals Inc. | 2025-06-01 | Phase 3 | NCT05667142 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures |